TY - JOUR
T1 - Sex and gender in inflammatory bowel disease outcomes and research
AU - Andersen, Vibeke
AU - Pingel, Jessica
AU - Søfelt, Heidi Lynge
AU - Hikmat, Zainab
AU - Johansson, Mads
AU - Pedersen, Vera Slyk
AU - Bertelsen, Benthe
AU - Carlsson, Anne
AU - Lindh, Marie
AU - Svavarsdóttir, Edda
AU - Repsilber, Dirk
AU - Joergensen, Maiken Thyregod
AU - Christensen, Robin
AU - Fejrskov, Anja
AU - Füchtbauer, Johannes David
AU - Kjeldsen, Jens
AU - Jensen, Michael Dam
AU - Aalykke, Claus
AU - Rejler, Martin
AU - Høivik, Marte Lie
AU - Davidsdottir, Loa
AU - Carlson, Marie
AU - Halfvarson, Jonas
AU - Zachariassen, Heidi Holt
AU - Petersen, Liv Baisner
AU - Myers, Eva Sophia
N1 - Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
PY - 2024/11
Y1 - 2024/11
N2 - Extensive patient heterogeneity is a challenge in the management of inflammatory bowel disease (IBD). Sex and gender, as well as the interaction of sex and gender with other social identities, referred to as intersectionality, contribute to this heterogeneity and might affect IBD outcomes. An interdisciplinary team of clinicians, researchers, patients, and sex and gender experts reviewed current literature on the effect of sex and gender dimensions on IBD outcomes. The team also investigated the role that stakeholders have in advancing sex-based and gender-based IBD knowledge, as comprehensive studies are scarce. Acknowledging and integrating sex and gender into the organisation and content of research (eg, study design, participant recruitment, data analysis, data interpretation, data dissemination, and impact evaluation) could enhance the validity, relevance, and applicability of research. Such gendered innovation has potential for advancing personalised medicine and improving the quality of life for people with IBD.
AB - Extensive patient heterogeneity is a challenge in the management of inflammatory bowel disease (IBD). Sex and gender, as well as the interaction of sex and gender with other social identities, referred to as intersectionality, contribute to this heterogeneity and might affect IBD outcomes. An interdisciplinary team of clinicians, researchers, patients, and sex and gender experts reviewed current literature on the effect of sex and gender dimensions on IBD outcomes. The team also investigated the role that stakeholders have in advancing sex-based and gender-based IBD knowledge, as comprehensive studies are scarce. Acknowledging and integrating sex and gender into the organisation and content of research (eg, study design, participant recruitment, data analysis, data interpretation, data dissemination, and impact evaluation) could enhance the validity, relevance, and applicability of research. Such gendered innovation has potential for advancing personalised medicine and improving the quality of life for people with IBD.
KW - Humans
KW - Inflammatory Bowel Diseases/psychology
KW - Sex Factors
KW - Female
KW - Male
KW - Quality of Life
KW - Biomedical Research
KW - Research Design
U2 - 10.1016/S2468-1253(24)00159-6
DO - 10.1016/S2468-1253(24)00159-6
M3 - Journal article
C2 - 39395438
SN - 2468-1253
VL - 9
SP - 1041
EP - 1051
JO - The Lancet Gastroenterology & Hepatology
JF - The Lancet Gastroenterology & Hepatology
IS - 11
ER -